Cite
HARVARD Citation
Moellmann, J. et al. (n.d.). The SGLT2 inhibitor ertugliflozin causes a switch of cardiac substrate utilization leading to reduced cardiac mTOR-signaling, unfolded protein response and apoptosis. European heart journal. p. . [Online].